Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Jan;29(1):44–48. doi: 10.1128/aac.29.1.44

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora.

B E Harris, B W Manning, T W Federle, R B Diasio
PMCID: PMC180361  PMID: 3729334

Abstract

The mechanism of toxicity from 5-fluorocytosine chemotherapy is unclear. However, recent evidence suggests that the generation of 5-fluorouracil by a host may play an important role in the development of this toxicity. Using an in vitro semicontinuous culture system to mimic the intestinal microflora, we examined the capacity of this complex microbial community to convert 5-fluorocytosine to 5-fluorouracil. The system was dosed initially and after 2 weeks of chronic exposure to 5-fluorocytosine with radiolabeled 5-fluorocytosine. No detectable production of 5-fluorouracil was observed up to 8 h after the acute dose; however, at 24 h and at all time points thereafter, increasing levels of 5-fluorouracil were detected for 4 days. The chronic dose resulted in an increased rate of 5-fluorouracil production without the 8-h lag time. These findings suggest that the enzyme or enzymes responsible for the deamination of 5-fluorocytosine to 5-fluorouracil by the intestinal microflora can be induced by chronic exposure to 5-fluorocytosine and that this conversion may provide a mechanism through which 5-fluorocytosine toxicity is manifested.

Full text

PDF
44

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennet J. E. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319–321. doi: 10.7326/0003-4819-86-3-319. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. E., Dismukes W. E., Duma R. J., Medoff G., Sande M. A., Gallis H., Leonard J., Fields B. T., Bradshaw M., Haywood H. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. doi: 10.1056/NEJM197907193010303. [DOI] [PubMed] [Google Scholar]
  3. Bethge P. O., Lindström K. Determination of organic acids of low relative molecular mass (C1 to C4) in dilute aqueous solution. Analyst. 1974 Feb;99(175):137–142. doi: 10.1039/an9749900137. [DOI] [PubMed] [Google Scholar]
  4. Block E. R., Jennings A. E., Bennett J. E. Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine. Antimicrob Agents Chemother. 1973 Jan;3(1):95–98. doi: 10.1128/aac.3.1.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cummings J. H., Hill M. J., Bone E. S., Branch W. J., Jenkins D. J. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr. 1979 Oct;32(10):2094–2101. doi: 10.1093/ajcn/32.10.2094. [DOI] [PubMed] [Google Scholar]
  6. DUOBOS R., SCHAEDLER R. W., COSTELLO R. COMPOSITION, ALTERATION, AND EFFECTS OF THE INTESTINAL FLORA. Fed Proc. 1963 Nov-Dec;22:1322–1329. [PubMed] [Google Scholar]
  7. Diasio R. B., Lakings D. E., Bennett J. E. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother. 1978 Dec;14(6):903–908. doi: 10.1128/aac.14.6.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Finch R. E., Bending M. R., Lant A. F. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol. 1979 Jun;7(6):613–617. doi: 10.1111/j.1365-2125.1979.tb04651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldman P. Biochemical pharmacology of the intestinal flora. Annu Rev Pharmacol Toxicol. 1978;18:523–539. doi: 10.1146/annurev.pa.18.040178.002515. [DOI] [PubMed] [Google Scholar]
  10. Kauffman C. A., Frame P. T. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977 Feb;11(2):244–247. doi: 10.1128/aac.11.2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Koechlin B. A., Rubio F., Palmer S., Gabriel T., Duschinsky R. The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man. Biochem Pharmacol. 1966 Apr;15(4):435–446. doi: 10.1016/0006-2952(66)90254-1. [DOI] [PubMed] [Google Scholar]
  12. Manning B. W., Cerniglia C. E., Federle T. W. Metabolism of the benzidine-based azo dye Direct Black 38 by human intestinal microbiota. Appl Environ Microbiol. 1985 Jul;50(1):10–15. doi: 10.1128/aem.50.1.10-15.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mauceri A. A., Cullen S. I., Vandevelde A. G., Johnson J. E., 3rd Flucytosine. An effective oral treatment for chromomycosis. Arch Dermatol. 1974 Jun;109(6):873–876. doi: 10.1001/archderm.109.6.873. [DOI] [PubMed] [Google Scholar]
  14. Miller T. L., Wolin M. J. Fermentation by the human large intestine microbial community in an in vitro semicontinuous culture system. Appl Environ Microbiol. 1981 Sep;42(3):400–407. doi: 10.1128/aem.42.3.400-407.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Donovan G. A., Neuhard J. Pyrimidine metabolism in microorganisms. Bacteriol Rev. 1970 Sep;34(3):278–343. doi: 10.1128/br.34.3.278-343.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Polak A., Eschenhof E., Fernex M., Scholer H. J. Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. Chemotherapy. 1976;22(3-4):137–153. doi: 10.1159/000221923. [DOI] [PubMed] [Google Scholar]
  17. Polak A., Eschenhof E., Fernex M., Scholer H. J. Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. Chemotherapy. 1976;22(3-4):137–153. doi: 10.1159/000221923. [DOI] [PubMed] [Google Scholar]
  18. Polak A., Scholer H. J. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3-4):113–130. doi: 10.1159/000221854. [DOI] [PubMed] [Google Scholar]
  19. Scheline R. R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev. 1973 Dec;25(4):451–523. [PubMed] [Google Scholar]
  20. Utz J. P., Garriques I. L., Sande M. A., Warner J. F., Mandell G. L., McGehee R. F., Duma R. J., Shadomy S. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis. 1975 Oct;132(4):368–373. doi: 10.1093/infdis/132.4.368. [DOI] [PubMed] [Google Scholar]
  21. Williams K. M., Duffield A. M., Christopher R. K., Finlayson P. J. Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry. Biomed Mass Spectrom. 1981 Apr;8(4):179–182. doi: 10.1002/bms.1200080410. [DOI] [PubMed] [Google Scholar]
  22. Zijlstra J. B., Beukema J., Wolthers B. G., Byrne B. M., Groen A., Dankert J. Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta. 1977 Jul 15;78(2):243–250. doi: 10.1016/0009-8981(77)90312-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES